Priska Auf der Maur
11PUBLICATIONS
37CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Dec 02, 2025
Tempered signal strength via low-dose MEK inhibition optimizes therapeutic performance of engineered T cells.Franziska Füchsl, Antonia Schwanzer, Melanie Faber
|Jul 16, 2024
FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.Anna Sperk, Antje Gabriel, Daniela Koch
|Oct 19, 2023
Unraveling T-cell Exhaustion: Genetic Screening Meets In Vitro Modeling.Dominic Schmid, Priska Auf der Maur, Marcel P Trefny
|Feb 02, 2023
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.Marcel P Trefny, Nicole Kirchhammer, Priska Auf der Maur
|Nov 09, 2022
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.Nicole Kirchhammer, Marcel P Trefny, Priska Auf der Maur
|Aug 25, 2022
A high-throughput drug screen reveals means to differentiate triple-negative breast cancer.Milica Vulin, Charly Jehanno, Atul Sethi
Pageof 2
Frequent Collaborators
7 joint publications
Mohamed Bentires-Alj
5 joint publications
Marcel P Trefny
5 joint publications
Alfred Zippelius
3 joint publications
Alexander Schmidt
2 joint publications
Ana Luísa Correia
2 joint publications
Joao C Guimaraes
2 joint publications
Kirsten Mertz
2 joint publications
Dominic Schmid
2 joint publications
Nicole Kirchhammer
1 joint publications
Charly Jehanno
